Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Multiple sclerosis
FollowWhat is new in Multiple sclerosis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
- Cure
- Treatable, not yet curableSource: EAN · 2026-11-04What these labels meanCurable in many cases – treatment can remove the disease completely for many patients.Treatable, not yet curable – treatment can slow the disease and extend life, but it cannot remove it completely yet.This pageNo cure yet – there is no treatment yet that stops the disease; care focuses on symptoms.
- Standard treatment
- Disease-modifying drugs to cut relapsesSource: EAN
Cure status
- 13-valent pneumococcal conjugate vaccine (13-PCV)Phase 3 · NCT03650114
- 23-valent pneumococcal polysaccharide vaccine (23-PPV)Phase 3 · NCT03650114
- ABP 692Phase 3 · NCT06700343
- Activated charcoalPhase 3 · NCT06141473
- AlemtuzumabPhase 3 · NCT03477500
- Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)Phase 3 · NCT07189325
- AntihistaminePhase 3 · NCT04548999 · NCT04544436
- ArbaclofenPhase 3 · NCT05179577
- Autologous Hematopoietic Stem Cell TransplantationPhase 3 · NCT00716066 · NCT04047628
- BCD-281Phase 3 · NCT07321093
- Best Available Therapy (BAT)Phase 3 · NCT04047628
- BIIB017 (peginterferon beta-1a)Phase 3 · NCT03958877
- CetirizinePhase 3 · NCT07472413
- CholestyraminePhase 3 · NCT06141473
- Cladribine PillPhase 3 · NCT03477500
- CT-P53Phase 3 · NCT05906992
- CYB704Phase 3 · NCT06847724
- Cyclophosphamide and ATGPhase 3 · NCT03477500
- Dalfampridine 10 MG [Ampyra]Phase 3 · NCT06136728
- Dimethyl FumaratePhase 3 · NCT07776743 · NCT07483632
- DiphenhydraminePhase 3 · NCT07472413
- Diroximel FumaratePhase 3 · NCT07483632
- DMT continuationPhase 3 · NCT03653273
- EU-OcrevusPhase 3 · NCT05906992 · NCT07606521
- FenebrutinibPhase 3 · NCT05119569 · NCT07161258 · NCT04586010 · NCT04586023 · NCT04544449
- FexofenadinePhase 3 · NCT04688788
- FingolimodPhase 3 · NCT06408259 · NCT04926818 · NCT07483632 · NCT05123703 · NCT01892722 · NCT07220252
- FrexalimabPhase 3 · NCT06141486 · NCT07325292 · NCT06141473
- IMU-838 tabletsPhase 3 · NCT05134441 · NCT05201638
- Interferon beta type 1aPhase 3 · NCT03958877
- Interferon beta-1aPhase 3 · NCT01892722
- Keyhole limpet hemocyanin (KLH) neo-antigenPhase 3 · NCT03650114
- MethylprednisolonePhase 3 · NCT07623668 · NCT04548999 · NCT04688788 · NCT04544436 · NCT02784210
- MRI contrast-enhancing agentsPhase 3 · NCT06141486 · NCT06141473
- MRI contrast-enhancing preparationsPhase 3 · NCT04879628 · NCT07325292
- OcrelizumabPhase 3 · NCT04075266 · NCT05269004 · NCT03477500 · NCT06675955 · NCT07321093 · NCT03523858 · NCT04035005 · NCT06846281 · NCT04548999 · NCT05123703 · NCT04688788 · NCT04544449 · NCT04544436 · NCT07282574 · NCT04578639 · NCT05210621
- Ocrelizumab (EU)Phase 3 · NCT06700343
- Ocrelizumab (US)Phase 3 · NCT06700343
- Ocrelizumab Injection [Ocrevus]Phase 3 · NCT05999604
- Ocrevus-EUPhase 3 · NCT06847724
- Ocrevus-USPhase 3 · NCT06847724
- OfatumumabPhase 3 · NCT03650114 · NCT07546110 · NCT04926818
- Ofatumumab approved dosePhase 3 · NCT06869785
- Ofatumumab new dosePhase 3 · NCT06869785
- OrelabrutinibPhase 3 · NCT07299019 · NCT07067463
- OzanimodPhase 3 · NCT06408259
- ParacetamolPhase 3 · NCT04688788
- Perfusion of treatment OcrelizumabPhase 3 · NCT05758831
- Perfusion of treatment RituximabPhase 3 · NCT05758831
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)Phase 3 · NCT07189325
- PrivosegtorPhase 3 · NCT07623668
- RemibrutinibPhase 3 · NCT05147220 · NCT05156281
- Remibrutinib (blinded)Phase 3 · NCT07225504
- Remibrutinib (Open label)Phase 3 · NCT07225504 · NCT07222956
- Remibrutinib oral treatmentPhase 3 · NCT06846281
- RituximabPhase 3 · NCT04688788 · NCT05834855 · NCT06599307 · NCT04578639
- Seasonal Quadrivalent influenza vaccinePhase 3 · NCT03650114
- SiponimodPhase 3 · NCT04926818
- TeriflunomidePhase 3 · NCT04586010 · NCT04586023 · NCT06141473 · NCT05147220 · NCT06372145 · NCT05156281
- Tetanus toxoid (TT) containing vaccine (Td, Tdap)Phase 3 · NCT03650114
- TolebrutinibPhase 3 · NCT06372145
- treatment withdrawalPhase 3 · NCT06663189
- UblituximabPhase 3 · NCT07211633 · NCT07503873 · NCT05877963 · NCT04130997 · NCT06629428 · NCT07220252
- US-OcrevusPhase 3 · NCT05906992 · NCT07606521
- Usual DMT continuationPhase 3 · NCT06663189
- 0.9% Chloride Injection SodiumPhase 2/3 · NCT05961644
- Cladribine (MAVENCLAD®)Phase 2/3 · NCT04695080
- Cladribine Subcutaneous InjectionPhase 2/3 · NCT05961644
- PET-MRI with [18F]-DPA-714Phase 2/3 · NCT06280742
- Active tDCSPhase 2 · NCT06901687
- Anti-CD20 mABPhase 2 · NCT06384976
- Anti-Thymocyte GlobulinPhase 2 · NCT00716066
- Autologous HB-adMSCsPhase 2 · NCT06800404
- Bacille Calmette-Guerin vaccinePhase 2 · NCT03888924
- BMS-986368Phase 2 · NCT06782490
- C-11 ER176 RadiotracerPhase 2 · NCT05805839
- C11 Pittsburgh Compound BPhase 2 · NCT05805839
- Cannabidiol (CBD)Phase 2 · NCT05269628
- Cannabis oil vs placeboPhase 2 · NCT05092191
- CarmustinePhase 2 · NCT00716066
- CBDPhase 2 · NCT06261489
- ClemastinePhase 2 · NCT02521311
- CytarabinePhase 2 · NCT00716066
- DMTsPhase 2 · NCT07263607
- DMTs + taurinePhase 2 · NCT07263607
- Efgartigimod AlfaPhase 2 · NCT06453694
- EtoposidePhase 2 · NCT00716066
- ForalumabPhase 2 · NCT06292923
- Foralumab TZLS-401 100 µgPhase 2 · NCT06890923
- HP 13C pyruvate injectionPhase 2 · NCT07510607
- IfenprodilPhase 2 · NCT06330077
- IMU-838 (10 mg/day)Phase 2 · NCT03846219
- IMU-838 (30 mg/day)Phase 2 · NCT03846219
- IMU-838 (45 mg/day)Phase 2 · NCT03846219
- IndapamidePhase 2 · NCT07765212
- KetaminePhase 2 · NCT05378100
- KYV-101Phase 2 · NCT06384976
- MelphalanPhase 2 · NCT00716066
- MetforminPhase 2 · NCT04121468 · NCT06463743
- Metformin Hydrochloride 850 mg Oral TabletPhase 2 · NCT05893225
- MidazolamPhase 2 · NCT05378100
- Modafinil Generis 100 mgPhase 2 · NCT06592352
- MRIPhase 2 · NCT03910738
- MRI ScannerPhase 2 · NCT07510607
- mRNA-1195Phase 2 · NCT06735248
- N-acetyl cysteinePhase 2 · NCT05122559
- Nasal Methylprednisolone (MT)Phase 2 · NCT06223074
- Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for InjectionPhase 2 · NCT03910738
- NG01 - Autologous bone marrow derived human stromal cellsPhase 2 · NCT06961383
- NLY01Phase 2 · NCT07497399
- ObexelimabPhase 2 · NCT06564311
- Ocrelizumab Co-formulated With rHuPH20Phase 2 · NCT07667322 · NCT07503340
- Ocrelizumab Reference FormulationPhase 2 · NCT07074886
- Ocrelizumab Test FormulationPhase 2 · NCT07074886
- Peripheral Blood Stem Cell TransplantationPhase 2 · NCT00716066
- PrednisonePhase 2 · NCT00716066 · NCT02784210
- Prefilled penPhase 2 · NCT07503873
- Psilocybin therapyPhase 2 · NCT06782724
- RE104 for InjectionPhase 2 · NCT07002034
- RO7268489Phase 2 · NCT07282574
- RocbrutinibPhase 2 · NCT07776743
- SAR441344 IVPhase 2 · NCT04879628
- SAR441344 SCPhase 2 · NCT04879628
- Sequential treatment with rituximab and cladribinePhase 2 · NCT07517185
- SolriamfetolPhase 2 · NCT06170970
- Standard First-line Disease-Modifying TherapyPhase 2 · NCT07827716
- Standard lymphodepletion regimenPhase 2 · NCT06384976 · NCT06138132
- SUN-627Phase 2 · NCT07840326
- Syngeneic Bone Marrow TransplantationPhase 2 · NCT00716066
- TerfenadinePhase 2 · NCT07827716
- Tetrahydrocannabinol (THC)Phase 2 · NCT05269628
- THCPhase 2 · NCT06261489
- Tolerogenic dendritic cells (tolDC)Phase 2 · NCT07020715
- Truvada (tenofovir/emtricitabine)Phase 2 · NCT05957913
- Tyruko Injectable ProductPhase 2 · NCT05418010
- [C-11]MethylreboxetinePhase 1/2 · NCT03207464
- [C-11]PBR28Phase 1/2 · NCT02649985
- [F-18]PBR06Phase 1/2 · NCT02649985
- 18F-OP-801Phase 1/2 · NCT05395624
- Allogeneic umbilical cord mesenchymal stem cellsPhase 1/2 · NCT05532943
- BendamustinePhase 1/2 · NCT07477639
- C-CAR168Phase 1/2 · NCT07825389
- CilostazolPhase 1/2 · NCT03109288
- Clemastine FumaratePhase 1/2 · NCT06065670 · NCT05359653
- Control groupPhase 1/2 · NCT05532943
- CTX112Phase 1/2 · NCT07804004
- DantrolenePhase 1/2 · NCT03109288
- LeucovorinPhase 1/2 · NCT03109288
- Low-Dose Naltrexone (LDN)Phase 1/2 · NCT07221565
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR)Phase 1/2 · NCT07221565
- MB-CART2019.1Phase 1/2 · NCT07178431
- PioglitazonePhase 1/2 · NCT03109288
- PirfenidonePhase 1/2 · NCT03109288
- PRO-1562 Oral CapsulesPhase 1/2 · NCT07826689
- rapcabtagene autoleucel (YTB323)Phase 1/2 · NCT06617793 · NCT06675864
- SalinePhase 1/2 · NCT04749667
- SYS6020 injectionPhase 1/2 · NCT07756268
- TRX319Phase 1/2 · NCT07477639
- VT7208Phase 1/2 · NCT07085507
- [ 18F]3F4APPhase 1 · NCT06999434
- [11C]PIBPhase 1 · NCT06999434
- [18F]MK6240Phase 1 · NCT06999434
- 89 Zr-Df-crefmirlimabPhase 1 · NCT05849467
- ABA-101Phase 1 · NCT06566261
- Adipose tissue-derived Mesenchymal Stromal CellsPhase 1 · NCT06592703
- AZD0120 - Regimen 1Phase 1 · NCT07224373
- AZD0120 - Regimen 2Phase 1 · NCT07224373
- Azercabtagene zapreleucel (azer-cel)Phase 1 · NCT06680037
- Biospecimen CollectionPhase 1 · NCT03816345
- CabozantinibPhase 1 · NCT03816345
- CC-97540Phase 1 · NCT06220201
- CD20/BCMA-directed CAR-T cellsPhase 1 · NCT07341828 · NCT06249438
- CD20/BCMA-directed CAR-T cells Autologous 2nd generationPhase 1 · NCT07676266
- Cellular therapy with EBV specific autologous CTL infusionPhase 1 · NCT02912897
- Chemotherapy: cyclophosphamide (CYC)Phase 1 · NCT06451159
- Chemotherapy: fludarabine (FLU)Phase 1 · NCT06451159
- CTA313 UCAR T Cell InfusionPhase 1 · NCT07783269
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cellsPhase 1 · NCT05003388
- CyclophosphamidePhase 1 · NCT07008378 · NCT07304154 · NCT06220201 · NCT07526493
- Dasatinib and quercetinPhase 1 · NCT07270120
- Deep brain stimulationPhase 1 · NCT05451251
- DPA-714 PET/MRIPhase 1 · NCT03759522
- F-18 3F4APPhase 1 · NCT04699747
- FludarabinePhase 1 · NCT07008378 · NCT07304154 · NCT06220201 · NCT07526493
- Fludarabine Phosphate for InjectionPhase 1 · NCT05832515
- FluoropyrimidinePhase 1 · NCT03816345
- glibenclamidePhase 1 · NCT07221799
- HBI0101 CARTPhase 1 · NCT07085676
- IMS001Phase 1 · NCT04956744
- IpilimumabPhase 1 · NCT03816345
- IVL3004Phase 1 · NCT05620940
- IVL4002Phase 1 · NCT05620940
- Ixazomib (NINLARO®) capsules / Matching placebo capsulesPhase 1 · NCT03783416
- KITE-363Phase 1 · NCT07304154
- KYV-101 (Biological) - 0.33 ×10^8 cellsPhase 1 · NCT06451159
- KYV-101 (Biological) - 1 ×10^8 cellsPhase 1 · NCT06451159
- KYV-101 anti-CD19 CAR-T cell therapyPhase 1 · NCT06138132
- Light therapyPhase 1 · NCT06261528
- myeloablative regimenPhase 1 · NCT06900192
- NivolumabPhase 1 · NCT03816345
- Obecabtagene autoleucel (obe-cel)Phase 1 · NCT07139743
- Ocrevus®Phase 1 · NCT07597668
- Orca-QPhase 1 · NCT06900192
- P-CD19CD20-ALLO1 CellsPhase 1 · NCT07008378
- PB018Phase 1 · NCT07606521
- Platinum CompoundPhase 1 · NCT03816345
- Platinum DoubletPhase 1 · NCT03816345
- Repetitive Transcranial Magnetic Stimulation (rTMS)Phase 1 · NCT07562074
- RO7121932 IVPhase 1 · NCT05704361
- RO7121932 SCPhase 1 · NCT05704361
- RO7845860Phase 1 · NCT07749157
- RPH-035Phase 1 · NCT07597668
- S103 cellsPhase 1 · NCT07587125
- Universal CD19 CAR-γδT Cell InjectionPhase 1 · NCT07526493
- Universal STAR-T Cell InjectionPhase 1 · NCT07523100
- VancomycinPhase 1 · NCT05539729
- Vivitrol Injectable ProductPhase 1 · NCT05620940
- [F-18]SDM-8Early phase 1 · NCT04634994
- Amyvid radiopharmaceuticalEarly phase 1 · NCT04390009
- CD19/BCMA-targeted CAR-T cellsEarly phase 1 · NCT07337785
- CT103A cellsEarly phase 1 · NCT04561557
- Cyclophosphamide and fludarabineEarly phase 1 · NCT04561557
- GC012F CAR-T Cell InjectionEarly phase 1 · NCT07303790
- GentamicinEarly phase 1 · NCT07643974
- GT802 InjectionEarly phase 1 · NCT07748637
- Lactobacillus Rhamnosus GGEarly phase 1 · NCT07643974
- Lymphodepleting ConditioningEarly phase 1 · NCT07337785
- NK042Early phase 1 · NCT07546110
- QT-019CEarly phase 1 · NCT07392528
- UCAR T-cellEarly phase 1 · NCT06939166
- Universal BCMA CAR-TEarly phase 1 · NCT06485232
- Universal BCMA CAR-T; Universal CD19 CAR-TEarly phase 1 · NCT06485232
- Universal CD19 CAR-TEarly phase 1 · NCT06485232
Closest to patients
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisSafety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisUCSF · San Francisco, United States + 61 more hospitalsPhase 3Primary completion 2017
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Neiro Clinica LLC · Moscow, Russia + 120 more hospitalsPhase 3Primary completion 2024
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisA Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisMedical Centre of PE First Private Clinic · Kyiv, Ukraine + 155 more hospitalsPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Systematic review
Stereotactic radiosurgery for bilateral trigeminal neuralgia: A systematic review and proposed framework for staged treatment.
Stereotactic radiosurgery for bilateral trigeminal neuralgia: A systematic review and proposed framework for staged treatment.
Neurosurgical review
PubMed · PMID 42972164Publication
A Belgian study assessing relapsing multiple sclerosis activity through automated magnetic resonance imaging volumetry.
A Belgian study assessing relapsing multiple sclerosis activity through automated magnetic resonance imaging volumetry.
Neurodegenerative disease management
PubMed · PMID 42968545Publication
Therapeutic Multifaceted Potential of Melatonin in Neurodegenerative Diseases: From Neuroprotective Mechanisms to Translational Promise.
Therapeutic Multifaceted Potential of Melatonin in Neurodegenerative Diseases: From Neuroprotective Mechanisms to Translational Promise.
Current medicinal chemistry
PubMed · PMID 42973361
Find fellow researchers
Groups with active Multiple sclerosis work.
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, San Francisco
San Francisco, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Tehran University of Medical Sciences
Tehran, Iran
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
UCL Queen Square Institute of Neurology
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Cleveland Clinic
Cleveland, United States
Team details appear once the team leader joins.
Is this your team? Claim it
IRCCS Ospedale San Raffaele
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Vita-Salute San Raffaele University
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it